COVID 19 infection in children causes a hyper-inflammatory syndrome referred to as multisystem inflammatory syndrome in children (MIS-C). This ACTION publication, published June 2, 2021 in Pediatric Cardiology, provides a set of recommendations concerning anticoagulation practices in kids with MIS-C: “Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action”
What You Need To Know:
- Children with MIS-C have laboratory findings that suggest a pro-coagulable state. However, the actual reports of thrombotic events in MIS-C patients have been rare.
- An ACTION committee gathered information concerning COVID-19 anticoagulation practices at ACTION centers and harmonized the data to formulate a set of recommendations.
Shout out to ACTION members from ACTION centers all over who co-authored this important collaborative work:
- Neha Bansal, Children’s Hospital at Montefiore
- Estela Azeka, Heart Institute, University of São Paulo
- Cindy Neunert, NewYork-Presbyterian Morgan Stanley Children’s Hospital
- John Kim, Children’s Hospital Colorado
- Jenna Murray, Lucile Packard Children’s Hospital
- Lindsay May, Primary Children’s Hospital
- Christa Kirk, Seattle Children’s Hospital
- Angela Lorts, Cincinnati Children’s
- David Rosenthal , Lucile Packard Children’s Hospital
- Christina VanderPluym, Boston Children’s Hospital
Bansal N, Azeka E, Neunert C, Kim JS, Murray J, May L, Kirk C, Lorts A, Rosenthal D, VanderPluym C. Multisystem Inflammatory Syndrome Associated with COVID-19 Anti-thrombosis Guideline of Care for Children by Action. Pediatr Cardiol. 2021 Jun 2:1–5. doi: 10.1007/s00246-021-02651-9. Epub ahead of print. PMID: 34076713; PMCID: PMC8169785.